Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
ZuKzfh7d3VpnCzbK
